tradingkey.logo

Neuropace Inc

NPCE
查看详细走势图
16.020USD
-0.170-1.05%
收盘 12/26, 16:00美东报价延迟15分钟
533.16M总市值
亏损市盈率 TTM

Neuropace Inc

16.020
-0.170-1.05%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.05%

5天

-3.44%

1月

-2.91%

6月

+49.58%

今年开始到现在

+43.16%

1年

+50.14%

查看详细走势图

TradingKey Neuropace Inc股票评分

单位: USD 更新时间: 2025-12-26

操作建议

Neuropace Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名47/207位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价17.50。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Neuropace Inc评分

相关信息

行业排名
47 / 207
全市场排名
147 / 4563
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 8 位分析师
买入
评级
17.500
目标均价
+6.51%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Neuropace Inc亮点

亮点风险
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
业绩高增长
公司营业收入稳步增长,连续3年增长75.54%
业绩增长期
公司处于发展阶段,最新年度总收入79.91M美元
估值低估
公司最新PE估值-21.36,处于3年历史低位
机构减仓
最新机构持股31.14M股,环比减少8.66%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值3.00K
活跃度降低
近期活跃度降低,过去20天平均换手率0.28

Neuropace Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Neuropace Inc简介

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
公司代码NPCE
公司Neuropace Inc
CEOBecker (Joel D)
网址https://www.neuropace.com/

常见问题

Neuropace Inc(NPCE)的当前股价是多少?

Neuropace Inc(NPCE)的当前股价是 16.020。

Neuropace Inc的股票代码是什么?

Neuropace Inc的股票代码是NPCE。

Neuropace Inc股票的52周最高点是多少?

Neuropace Inc股票的52周最高点是18.975。

Neuropace Inc股票的52周最低点是多少?

Neuropace Inc股票的52周最低点是7.563。

Neuropace Inc的市值是多少?

Neuropace Inc的市值是533.16M。

Neuropace Inc的净利润是多少?

Neuropace Inc的净利润为-27.14M。

现在Neuropace Inc(NPCE)的股票是买入、持有还是卖出?

根据分析师评级,Neuropace Inc(NPCE)的总体评级为买入,目标价格为17.500。

Neuropace Inc(NPCE)股票的每股收益(EPS TTM)是多少

Neuropace Inc(NPCE)股票的每股收益(EPS TTM)是-0.750。
KeyAI